Ginkgo Bioworks (DNA) Competitors

$8.42 +0.01 (+0.08%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$8.65 +0.24 (+2.82%)

As of 05/22/2026 07:53 PM Eastern

DNA vs. TWST, OCUL, PHVS, AUPH, and MESO

Should you buy Ginkgo Bioworks stock or one of its competitors? MarketBeat compares Ginkgo Bioworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ginkgo Bioworks include Twist Bioscience (TWST), Ocular Therapeutix (OCUL), Pharvaris (PHVS), Aurinia Pharmaceuticals (AUPH), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry.

How does Ginkgo Bioworks compare to Twist Bioscience?

Ginkgo Bioworks (NYSE:DNA) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Twist Bioscience had 3 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 5 mentions for Twist Bioscience and 2 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 0.89 beat Ginkgo Bioworks' score of 0.77 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ginkgo Bioworks has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.22, meaning that its share price is 122% more volatile than the broader market.

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.23	-$312.76M	-$5.36	N/A
Twist Bioscience	$376.57M	10.02	-$77.67M	-$1.33	N/A

Ginkgo Bioworks presently has a consensus price target of $8.50, suggesting a potential upside of 0.99%. Twist Bioscience has a consensus price target of $58.00, suggesting a potential downside of 4.24%. Given Ginkgo Bioworks' higher possible upside, analysts plainly believe Ginkgo Bioworks is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Twist Bioscience has a net margin of -19.85% compared to Ginkgo Bioworks' net margin of -215.41%. Twist Bioscience's return on equity of -26.73% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Twist Bioscience	-19.85%	-26.73%	-19.15%

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Twist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Ocular Therapeutix?

Ginkgo Bioworks (NYSE:DNA) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ocular Therapeutix has lower revenue, but higher earnings than Ginkgo Bioworks. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.23	-$312.76M	-$5.36	N/A
Ocular Therapeutix	$51.95M	34.69	-$265.94M	-$1.46	N/A

Ginkgo Bioworks has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Ginkgo Bioworks has a net margin of -215.41% compared to Ocular Therapeutix's net margin of -558.24%. Ginkgo Bioworks' return on equity of -56.08% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 2 articles in the media. Ginkgo Bioworks' average media sentiment score of 0.77 beat Ocular Therapeutix's score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ginkgo Bioworks currently has a consensus target price of $8.50, suggesting a potential upside of 0.99%. Ocular Therapeutix has a consensus target price of $23.78, suggesting a potential upside of 188.92%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Ginkgo Bioworks beats Ocular Therapeutix on 9 of the 15 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pharvaris currently has a consensus target price of $49.18, indicating a potential upside of 65.71%. Ginkgo Bioworks has a consensus target price of $8.50, indicating a potential upside of 0.99%. Given Pharvaris' stronger consensus rating and higher probable upside, equities research analysts clearly believe Pharvaris is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Pharvaris has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

In the previous week, Pharvaris had 15 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 17 mentions for Pharvaris and 2 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.77 beat Pharvaris' score of 0.43 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has higher earnings, but lower revenue than Ginkgo Bioworks. Pharvaris is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Ginkgo Bioworks	$170.15M	3.23	-$312.76M	-$5.36	N/A

Pharvaris has a beta of -2.34, meaning that its stock price is 334% less volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

Summary

Ginkgo Bioworks beats Pharvaris on 8 of the 15 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aurinia Pharmaceuticals presently has a consensus price target of $17.25, indicating a potential upside of 13.34%. Ginkgo Bioworks has a consensus price target of $8.50, indicating a potential upside of 0.99%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Aurinia Pharmaceuticals is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Aurinia Pharmaceuticals has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Aurinia Pharmaceuticals has higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	6.92	$287.20M	$2.17	7.01
Ginkgo Bioworks	$170.15M	3.23	-$312.76M	-$5.36	N/A

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 2 mentions for Ginkgo Bioworks. Aurinia Pharmaceuticals' average media sentiment score of 1.06 beat Ginkgo Bioworks' score of 0.77 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Ginkgo Bioworks' net margin of -215.41%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

Summary

Aurinia Pharmaceuticals beats Ginkgo Bioworks on 13 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Mesoblast?

Ginkgo Bioworks (NYSE:DNA) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Ginkgo Bioworks currently has a consensus target price of $8.50, indicating a potential upside of 0.99%. Given Ginkgo Bioworks' higher possible upside, research analysts plainly believe Ginkgo Bioworks is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Ginkgo Bioworks has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market.

In the previous week, Ginkgo Bioworks had 2 more articles in the media than Mesoblast. MarketBeat recorded 2 mentions for Ginkgo Bioworks and 0 mentions for Mesoblast. Ginkgo Bioworks' average media sentiment score of 0.77 beat Mesoblast's score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Ginkgo Bioworks	Positive
Mesoblast	Neutral

Mesoblast has lower revenue, but higher earnings than Ginkgo Bioworks. Mesoblast is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.23	-$312.76M	-$5.36	N/A
Mesoblast	$17.20M	114.41	-$102.14M	-$0.54	N/A

Mesoblast has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Mesoblast's return on equity of 0.00% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Mesoblast	N/A	N/A	N/A

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Mesoblast beats Ginkgo Bioworks on 10 of the 17 factors compared between the two stocks.

Get Ginkgo Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNA vs. The Competition

Export

Metric	Ginkgo Bioworks	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$549.37M	$3.37B	$6.46B	$23.20B
Dividend Yield	N/A	2.26%	2.76%	4.10%
P/E Ratio	-1.57	18.74	21.21	30.65
Price / Sales	3.23	323.98	554.38	24.50
Price / Cash	N/A	125.17	43.49	25.12
Price / Book	1.24	7.09	10.37	4.74
Net Income	-$312.76M	$24.45M	$3.57B	$1.07B
7 Day Performance	14.50%	6.38%	6.40%	2.36%
1 Month Performance	7.02%	2.43%	3.53%	1.58%
1 Year Performance	20.41%	62.98%	34.04%	28.42%

Ginkgo Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNA Ginkgo Bioworks	1.2198 of 5 stars	$8.42 +0.1%	$8.50 +1.0%	+20.4%	$549.37M	$170.15M	N/A	640	Gap Down
TWST Twist Bioscience	1.724 of 5 stars	$49.79 +1.3%	$56.57 +13.6%	+114.3%	$3.06B	$376.57M	N/A	990	Gap Down
OCUL Ocular Therapeutix	2.3173 of 5 stars	$8.38 -8.5%	$23.78 +183.7%	+12.7%	$2.01B	$51.95M	N/A	230
PHVS Pharvaris	3.9306 of 5 stars	$28.81 -5.2%	$49.18 +70.7%	+85.6%	$1.99B	N/A	N/A	30	Gap Up
AUPH Aurinia Pharmaceuticals	3.062 of 5 stars	$15.60 +2.1%	$17.25 +10.6%	+88.4%	$1.97B	$283.05M	7.19	300	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DNA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, OCUL, PHVS, AUPH, and MESO

How does Ginkgo Bioworks compare to Twist Bioscience?

Summary

How does Ginkgo Bioworks compare to Ocular Therapeutix?

Summary

How does Ginkgo Bioworks compare to Pharvaris?

Summary

How does Ginkgo Bioworks compare to Aurinia Pharmaceuticals?

Summary

How does Ginkgo Bioworks compare to Mesoblast?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, OCUL, PHVS, AUPH, and MESO

How does Ginkgo Bioworks compare to Twist Bioscience?

Does the media prefer DNA or TWST?

Which has more volatility and risk, DNA or TWST?

Which has preferable earnings and valuation, DNA or TWST?

Do analysts prefer DNA or TWST?

Is DNA or TWST more profitable?

Do insiders and institutionals hold more shares of DNA or TWST?

Summary

How does Ginkgo Bioworks compare to Ocular Therapeutix?

Do insiders & institutionals hold more shares of DNA or OCUL?

Which has stronger valuation and earnings, DNA or OCUL?

Which has more risk & volatility, DNA or OCUL?

Is DNA or OCUL more profitable?

Does the media prefer DNA or OCUL?

Do analysts prefer DNA or OCUL?

Summary

How does Ginkgo Bioworks compare to Pharvaris?

Do insiders and institutionals have more ownership in PHVS or DNA?

Do analysts prefer PHVS or DNA?

Is PHVS or DNA more profitable?

Does the media prefer PHVS or DNA?

Which has better valuation and earnings, PHVS or DNA?

Which has more risk and volatility, PHVS or DNA?

Summary

How does Ginkgo Bioworks compare to Aurinia Pharmaceuticals?

Do insiders and institutionals have more ownership in AUPH or DNA?

Do analysts recommend AUPH or DNA?

Which has more volatility and risk, AUPH or DNA?

Which has higher earnings and valuation, AUPH or DNA?

Does the media favor AUPH or DNA?

Is AUPH or DNA more profitable?

Summary

How does Ginkgo Bioworks compare to Mesoblast?

Do analysts rate DNA or MESO?

Which has more risk & volatility, DNA or MESO?

Does the media refer more to DNA or MESO?

Which has higher valuation & earnings, DNA or MESO?

Is DNA or MESO more profitable?

Do insiders and institutionals believe in DNA or MESO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools